Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to cardiovascular risk reduction in patients with type 2 diabetes (T2D). However, their underlying molecular mechanisms remain unclear. This study aimed to evaluate the effects of empagliflozin, a novel potent and selective iSGLT-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Canet, Francisco, Iannantuoni, Francesca, de Marañon, Aránzazu Martínez, Díaz-Pozo, Pedro, López-Domènech, Sandra, Vezza, Teresa, Navarro, Blanca, Solá, Eva, Falcón, Rosa, Bañuls, Celia, Morillas, Carlos, Rocha, Milagros, Víctor, Víctor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389001/
https://www.ncbi.nlm.nih.gov/pubmed/34439476
http://dx.doi.org/10.3390/antiox10081228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389001/
https://www.ncbi.nlm.nih.gov/pubmed/34439476
http://dx.doi.org/10.3390/antiox10081228

Ejemplares similares